A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

NCT02099071

Healthy Subjects

COMPLETED PHASE1

A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants

NCT01732237

Healthy

COMPLETED PHASE1

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507

Netherton Syndrome

RECRUITING PHASE1

A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects

NCT00854659

Healthy Volunteers

COMPLETED PHASE1

Study of NST-6179 in Healthy Subjects

NCT05181085

Short Bowel Syndrome Parenteral Nutrition Associated Liver Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AC 170 0.24%

Group Type EXPERIMENTAL

AC 170 0.24%

Intervention Type DRUG

1 drop in each eye 2 times daily for 1 week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AC 170 0.24%

1 drop in each eye 2 times daily for 1 week

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* at least 18 and no older than 55 years of age
* be able to self-administer eye drops or have a parent/legal guardian available for this purpose
* have blood and urine analysis within normal limits
* have ocular health within normal limits

Exclusion Criteria

* known contraindications or sensitivities to the study medication or its components
* have any active systemic or ocular disorder (other than refractive disorder)
* have inability to comply with controlled diet
* have used prescription or non prescription drugs within washout period and throughout study
* have used alcohol or tobacco within the washout period

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No